Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Feb;84(3):1631-6.
doi: 10.1128/JVI.01482-09. Epub 2009 Nov 18.

Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables

Affiliations

Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables

Nicole A Doria-Rose et al. J Virol. 2010 Feb.

Abstract

Induction of antibodies that neutralize a broad range of human immunodeficiency virus type 1 (HIV-1) isolates is a major goal of vaccine development. To study natural examples of broad neutralization, we analyzed sera from 103 HIV-1-infected subjects. Among progressor patients, 20% of sera neutralized more than 75% of a panel of 20 diverse viral isolates. Little activity was observed in sera from long-term nonprogressors (elite controllers). Breadth of neutralization was correlated with viral load, but not with CD4 count, history of past antiretroviral use, age, gender, race/ethnicity, or route of exposure. Clustering analysis of sera by a novel method identified a statistically robust subgrouping of sera that demonstrated broad and potent neutralization activity.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Neutralization of 20 isolates by patient sera. (A and B) ID50 value against each of 20 isolates in the TZM-bl assay is plotted for each patient. The red line indicates an ID50 of 100. Input dilution was 1:10; if no neutralization was observed, the ID50 is plotted as 5. (A) Progressors. (B) LTNP. (C) Viral load (RNA copies/ml plasma) versus geometric mean titer for each patient's serum. Red circles, LTNP; black circles, progressor patients.
FIG. 2.
FIG. 2.
Heat map and clustering analysis of serum. ID50 values of 103 sera against 20 isolates are shown. Each row of the heat map shows ID50 values for a single serum, and columns show virus isolates. Darker colors represent stronger neutralization (see key). The vertical order of sera is based on geometric mean titer; placement of clusters within this ranking uses the mean titer for all cluster members. The bars labeled “Bootstrap” or “Noise” show the results of statistical analysis of clustering. Both are visualized by mixing red, yellow, and blue corresponding to the relative frequencies of matched group assignments. A bright red, yellow, or blue color is a categorization that is unambiguous. Sera or isolates are grouped if they have a categorization of 90% or greater consistency by both the bootstrap and noise tests. Boxes highlight the clusters. Sera in red type are from LTNP. Clusters of patient sera are labeled P1, P2, and P3, while clusters of isolates are labeled I1, I2, and I3.
FIG. 3.
FIG. 3.
Heat map and clustering analysis of monoclonal antibodies and sCD4. Each row of the heat map shows IC50 values for a single reagent, and columns show virus isolates. See legend to Fig. 2 for an explanation. Boxes show isolates assigned to clusters at the 75% level. Neutralization data are from references and and this study.

Similar articles

Cited by

References

    1. Bailey, J. R., K. G. Lassen, H. C. Yang, T. C. Quinn, S. C. Ray, J. N. Blankson, and R. F. Siliciano. 2006. Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy. J. Virol. 80:4758-4770. - PMC - PubMed
    1. Bailey, J. R., T. M. Williams, R. F. Siliciano, and J. N. Blankson. 2006. Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations. J. Exp. Med. 203:1357-1369. - PMC - PubMed
    1. Beirnaert, E., P. Nyambi, B. Willems, L. Heyndrickx, R. Colebunders, W. Janssens, and G. van Der Groen. 2000. Identification and characterization of sera from HIV-infected individuals with broad cross-neutralizing activity against group M (env clade A-H) and group O primary HIV-1 isolates. J. Med. Virol. 62:14-24. - PubMed
    1. Binley, J. M., E. A. Lybarger, E. T. Crooks, M. S. Seaman, E. Gray, K. L. Davis, J. M. Decker, D. Wycuff, L. Harris, N. Hawkins, B. Wood, C. Nathe, D. Richman, G. D. Tomaras, F. Bibollet-Ruche, J. E. Robinson, L. Morris, G. M. Shaw, D. C. Montefiori, and J. R. Mascola. 2008. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J. Virol. 82:11651-11668. - PMC - PubMed
    1. Binley, J. M., T. Wrin, B. Korber, M. B. Zwick, M. Wang, C. Chappey, G. Stiegler, R. Kunert, S. Zolla-Pazner, H. Katinger, C. J. Petropoulos, and D. R. Burton. 2004. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78:13232-13252. - PMC - PubMed

Publication types

Substances